Y-mAbs to Report Second Quarter 2025 Results
Y-mAbs Therapeutics, Inc. (YMAB), a commercial-stage biopharmaceutical company, is set to announce its financial and operating results for the second quarter of 2025. The announcement will be made before the market opens on Friday of that week.
Focus on Innovative Cancer Therapies
Y-mAbs is dedicated to developing and commercializing cutting-edge antibody-based therapeutics specifically targeting cancer. Their commitment is reflected in their ongoing efforts to expand their product pipeline while providing new hope to patients facing challenging diagnoses.
Significant Product Pipeline
The company’s leading product, DANYELZA (naxitamab-gqgk), is recognized as the first FDA-approved therapy designed for patients suffering from relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. This advancement marks a significant milestone in cancer treatment, showcasing the potential of Y-mAbs' innovative approach.
Technological Advancements
Y-mAbs continues to innovate through its proprietary platforms including the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy (PRIT). This technology aims to increase the efficiency of cancer treatments by utilizing bispecific antibodies generated from their Y-BiClone platform, further enhancing patient outcomes.
Trademarked Technologies
The company proudly holds several registered trademarks such as DANYELZA and SADA®, symbolizing their commitment to quality and innovation within the industry. This recognition from regulatory bodies highlights the rigorous standards upheld by Y-mAbs in its treatment solutions.
Investor Relations and Communication
In a recent update, Y-mAbs has emphasized that they will not be hosting an earnings conference call in conjunction with the announcement due to the previously disclosed transaction with SERB Pharmaceuticals. This decision reflects a strategic focus on targeted communication and efficient use of resources.
Company Contacts for Investor Relations
For additional information, stakeholders and interested parties can reach out to:
Courtney Dugan, VP, Head of Investor Relations, via email at cdu@ymabs.com.
Alternatively, Aaron Palash or Fouad Boutros can be contacted at Joele Frank, Wilkinson Brimmer Katcher through the emails apalash@joelefrank.com and fboutros@joelefrank.com or by phone at 212-355-4449.
Conclusion
As Y-mAbs Therapeutics gears up for its significant second-quarter results, the focus on their innovative cancer therapies and the advanced technological platforms sets a hopeful tone for investors and patients alike. By prioritizing communication and transparency, they promise to keep their stakeholders informed while actively working towards groundbreaking solutions in cancer treatment.
Frequently Asked Questions
1. What is Y-mAbs Therapeutics?
Y-mAbs Therapeutics is a biopharmaceutical company focused on developing antibody-based treatments for cancer.
2. When will Y-mAbs announce its second-quarter results?
The announcement will be made before the market opens on the specified Friday.
3. What is DANYELZA and why is it significant?
DANYELZA is the first FDA-approved treatment for high-risk neuroblastoma, showcasing the effectiveness of Y-mAbs' therapeutics.
4. What technologies does Y-mAbs utilize?
The company employs innovative platforms such as SADA PRIT and Y-BiClone, enhancing their therapeutic offerings.
5. Who can I contact for investor relations at Y-mAbs?
Contact Courtney Dugan at cdu@ymabs.com for inquiries regarding investor relations.
